HER2 蛋白表达和基因扩增状态是乳腺癌分型、临床治疗、预后判断的重要参考依据。随着抗 HER2 靶向治疗的进展以及循证医学证据的更新，HER2 的检测与诊断亟需进一步规范。在此背景下，《乳腺癌 HER2 检测指南（2024 版）》为临床 HER2 检测给予规范指导，旨在提高 HER2 ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Lunit’s SCOPE HER2 AI model demonstrated an 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC).

爆竹声中一岁除。 得益于全球肿瘤学者的不懈努力和开拓创新，2024 年肿瘤诊疗取得了突破性的发展， 乳腺癌 领域亦是如此。多款创新药研发、多个新靶点探索，开创了乳腺癌诊疗的崭新局面。为回顾 2024 年乳腺癌重磅学术进展，分析乳腺癌临床治疗新格局，沉淀乳腺癌智慧结晶，使先进疗法更早惠及临床，同时指引未来乳腺癌领域研究探索方向， 「丁香园」、「长江学术带乳腺联盟」 联合举办 「破茧成蝶 ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...